

ANNEX

**CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED
BY THE MEMBER STATES**

CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES

The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented:

The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are expected to prescribe/use Cimzia are provided with a physician information pack containing the following:

- The Summary of Product Characteristics
- Physician information
- Patient Alert Card

The physician information should contain the following key messages:

- The risk of serious infections, including opportunistic bacterial, viral and fungal infections in patients treated with Cimzia,
- The need to evaluate patients for both active and inactive tuberculosis prior to starting the treatment, including use of appropriate screening tests,
- The contraindication of Cimzia in patients with history of moderate to severe heart failure (NYHA III/IV), and potential risk of congestive heart failure being worsened by Cimzia,
- The risk of acute injection-related reactions and delayed serious systemic hypersensitivity reactions, the need for instructing patients on techniques for administration, and guidance for Health Care Professionals on how to report administration errors,
- The role and use of patient alert card.